DAWN AC Rivaroxaban Module Launched
4S DAWN Clinical Software has launched a new module that supports the safe and efficient management of Rivaroxaban (Xarelto®). Developed in partnership with Bayer Healthcare, the module is designed specifically for healthcare professionals involved in the clinical treatment of patients with deep vein thrombosis (DVT), pulmonary embolism (PE) and the prevention of stroke in patients suffering from atrial fibrillation (AF).
Easy-to-use questionnaires and checklists incorporated into the patients overall treatment plan ensure a consistent approach throughout each stage of the patient journey from initiation to follow-up enabling protocol-driven care and improving the consistency of dosing practices. Further benefits include allowing healthcare professionals to track adherence, patient feedback and monitor side effects to increase patient safety and reduce clinical risk.
Whilst the novel oral anticoagulants (NOACs) require substantially less monitoring than traditional Warfarin treatment, adherence issues with long term medication generally, are well documented, with adherence likely to decrease over time. Repeat appointments a few months after starting on NOACs to verify that the patients are both taking and tolerating the medication, along with annual follow-ups to evaluate adherence and discuss the importance of the medication in preventing strokes, could counteract such adherence issues (Schulman et al 2013).
Syd Stewart, Managing Director at 4S DAWN Clinical Software believes that the new Rivaroxaban module addresses this,” The questionnaires that make up the module ensure that pertinent information such as comorbidities, interacting concomitant medication, possible side-effects and adherence are recorded easily and are highly visible within the patient’s treatment plan. This provides the healthcare professional with a safe and easy approach for prescribing NOACs”.
A Dabigatran module is also available from 4S DAWN and both modules tightly integrate with DAWN AC Anticoagulation Management Software to ensure safe prescribing and follow-up of patients on these new agents.